Literature DB >> 25401511

Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.

Lorraine V Kalia1, Anthony E Lang1, Lili-Naz Hazrati2, Shinsuke Fujioka3, Zbigniew K Wszolek3, Dennis W Dickson3, Owen A Ross3, Vivianna M Van Deerlin4, John Q Trojanowski4, Howard I Hurtig4, Roy N Alcalay5, Karen S Marder5, Lorraine N Clark5, Carles Gaig6, Eduardo Tolosa6, Javier Ruiz-Martínez7, Jose F Marti-Masso7, Isidre Ferrer8, Adolfo López de Munain7, Samuel M Goldman9, Birgitt Schüle10, J William Langston10, Jan O Aasly11, Maria T Giordana12, Vincenzo Bonifati13, Andreas Puschmann14, Margherita Canesi15, Gianni Pezzoli15, Andre Maues De Paula16, Kazuko Hasegawa17, Charles Duyckaerts18, Alexis Brice18, A Jon Stoessl19, Connie Marras1.   

Abstract

IMPORTANCE: Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of genetic Parkinson disease (PD) known to date. The clinical features of manifesting LRRK2 mutation carriers are generally indistinguishable from those of patients with sporadic PD. However, some PD cases associated with LRRK2 mutations lack Lewy bodies (LBs), a neuropathological hallmark of PD. We investigated whether the presence or absence of LBs correlates with different clinical features in LRRK2-related PD. OBSERVATIONS: We describe genetic, clinical, and neuropathological findings of 37 cases of LRRK2-related PD including 33 published and 4 unpublished cases through October 2013. Among the different mutations, the LRRK2 p.G2019S mutation was most frequently associated with LB pathology. Nonmotor features of cognitive impairment/dementia, anxiety, and orthostatic hypotension were correlated with the presence of LBs. In contrast, a primarily motor phenotype was associated with a lack of LBs. CONCLUSIONS AND RELEVANCE: To our knowledge, this is the first report of clinicopathological correlations in a series of LRRK2-related PD cases. Findings from this selected group of patients with PD demonstrated that parkinsonian motor features can occur in the absence of LBs. However, LB pathology in LRRK2-related PD may be a marker for a broader parkinsonian symptom complex including cognitive impairment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25401511      PMCID: PMC4399368          DOI: 10.1001/jamaneurol.2014.2704

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  21 in total

1.  Relationships between age and late progression of Parkinson's disease: a clinico-pathological study.

Authors:  Peter A Kempster; Sean S O'Sullivan; Janice L Holton; Tamas Revesz; Andrew J Lees
Journal:  Brain       Date:  2010-04-05       Impact factor: 13.501

2.  Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment.

Authors:  Anna Gomez; Isidre Ferrer
Journal:  Acta Neuropathol       Date:  2010-03-16       Impact factor: 17.088

3.  Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain).

Authors:  Javier Ruiz-Martínez; Ana Gorostidi; Berta Ibañez; Ainhoa Alzualde; David Otaegui; Fermin Moreno; Adolfo López de Munain; Alberto Bergareche; Juan Carlos Gómez-Esteban; José F Martí Massó
Journal:  Mov Disord       Date:  2010-10-30       Impact factor: 10.338

4.  A clinico-pathological study of subtypes in Parkinson's disease.

Authors:  M Selikhova; D R Williams; P A Kempster; J L Holton; T Revesz; A J Lees
Journal:  Brain       Date:  2009-09-16       Impact factor: 13.501

Review 5.  The Parkinson's complex: parkinsonism is just the tip of the iceberg.

Authors:  J William Langston
Journal:  Ann Neurol       Date:  2006-04       Impact factor: 10.422

Review 6.  The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.

Authors:  Mark R Cookson
Journal:  Nat Rev Neurosci       Date:  2010-11-19       Impact factor: 34.870

7.  A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1.

Authors:  Manabu Funayama; Kazuko Hasegawa; Hisayuki Kowa; Masaaki Saito; Shoji Tsuji; Fumiya Obata
Journal:  Ann Neurol       Date:  2002-03       Impact factor: 10.422

Review 8.  Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria.

Authors:  Dennis W Dickson; Heiko Braak; John E Duda; Charles Duyckaerts; Thomas Gasser; Glenda M Halliday; John Hardy; James B Leverenz; Kelly Del Tredici; Zbigniew K Wszolek; Irene Litvan
Journal:  Lancet Neurol       Date:  2009-12       Impact factor: 44.182

9.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.

Authors:  Daniel G Healy; Mario Falchi; Sean S O'Sullivan; Vincenzo Bonifati; Alexandra Durr; Susan Bressman; Alexis Brice; Jan Aasly; Cyrus P Zabetian; Stefano Goldwurm; Joaquim J Ferreira; Eduardo Tolosa; Denise M Kay; Christine Klein; David R Williams; Connie Marras; Anthony E Lang; Zbigniew K Wszolek; Jose Berciano; Anthony H V Schapira; Timothy Lynch; Kailash P Bhatia; Thomas Gasser; Andrew J Lees; Nicholas W Wood
Journal:  Lancet Neurol       Date:  2008-06-06       Impact factor: 44.182

Review 10.  Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.

Authors:  Daniela Berg; Ronald B Postuma; Bastiaan Bloem; Piu Chan; Bruno Dubois; Thomas Gasser; Christopher G Goetz; Glenda M Halliday; John Hardy; Anthony E Lang; Irene Litvan; Kenneth Marek; José Obeso; Wolfgang Oertel; C Warren Olanow; Werner Poewe; Matthew Stern; Günther Deuschl
Journal:  Mov Disord       Date:  2014-03-11       Impact factor: 10.338

View more
  95 in total

1.  Multisystem Lewy body disease and the other parkinsonian disorders.

Authors:  J William Langston; Birgitt Schüle; Linda Rees; R Jeremy Nichols; Carrolee Barlow
Journal:  Nat Genet       Date:  2015-12       Impact factor: 38.330

Review 2.  LRRK2 in Parkinson disease: challenges of clinical trials.

Authors:  Eduardo Tolosa; Miquel Vila; Christine Klein; Olivier Rascol
Journal:  Nat Rev Neurol       Date:  2020-01-24       Impact factor: 42.937

Review 3.  Mechanistic insights into the pathogenesis of neurodegenerative diseases: towards the development of effective therapy.

Authors:  Fauzia Nazam; Sibhghatulla Shaikh; Nazia Nazam; Abdulaziz Saad Alshahrani; Gulam Mustafa Hasan; Md Imtaiyaz Hassan
Journal:  Mol Cell Biochem       Date:  2021-03-09       Impact factor: 3.396

4.  Kinase inhibition of G2019S-LRRK2 enhances autolysosome formation and function to reduce endogenous alpha-synuclein intracellular inclusions.

Authors:  Julia Obergasteiger; Giulia Frapporti; Giulia Lamonaca; Sara Pizzi; Anne Picard; Alexandros A Lavdas; Francesca Pischedda; Giovanni Piccoli; Sabine Hilfiker; Evy Lobbestael; Veerle Baekelandt; Andrew A Hicks; Corrado Corti; Peter P Pramstaller; Mattia Volta
Journal:  Cell Death Discov       Date:  2020-06-08

Review 5.  Neuropathology of Parkinson disease.

Authors:  Dennis W Dickson
Journal:  Parkinsonism Relat Disord       Date:  2017-08-01       Impact factor: 4.891

Review 6.  Selective neuronal vulnerability in Parkinson disease.

Authors:  D James Surmeier; José A Obeso; Glenda M Halliday
Journal:  Nat Rev Neurosci       Date:  2017-01-20       Impact factor: 34.870

7.  Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease.

Authors:  Claudia Carricarte Naranjo; Connie Marras; Naomi P Visanji; David J Cornforth; Lazaro Sanchez-Rodriguez; Birgitt Schüle; Samuel M Goldman; Mario Estévez; Phyllis K Stein; Anthony E Lang; Herbert F Jelinek; Andrés Machado
Journal:  Clin Auton Res       Date:  2019-08-23       Impact factor: 4.435

8.  Olfactory Dysfunction in Parkinson's Disease Patients with the LRRK2 G2385R Variant.

Authors:  Ming Cao; Zhu-Qin Gu; Yuan Li; Hui Zhang; Xiao-Juan Dan; Shan-Shan Cen; Da-Wei Li; Piu Chan
Journal:  Neurosci Bull       Date:  2016-10-03       Impact factor: 5.203

9.  LRRK2 variation and dementia with Lewy bodies.

Authors:  Michael G Heckman; Alexandra I Soto-Ortolaza; Monica Y Sanchez Contreras; Melissa E Murray; Otto Pedraza; Nancy N Diehl; Ronald Walton; Catherine Labbé; Oswaldo Lorenzo-Betancor; Ryan J Uitti; Jay van Gerpen; Nilüfer Ertekin-Taner; Glenn E Smith; Kejal Kantarci; Rodolfo Savica; David T Jones; Jonathan Graff-Radford; David S Knopman; Val J Lowe; Clifford R Jack; Ronald C Petersen; Joseph E Parisi; Rosa Rademakers; Zbigniew K Wszolek; Neill R Graff-Radford; Tanis J Ferman; Dennis W Dickson; Bradley F Boeve; Owen A Ross
Journal:  Parkinsonism Relat Disord       Date:  2016-07-29       Impact factor: 4.891

Review 10.  Olfactory Dysfunction in Neurodegenerative Diseases.

Authors:  Concepció Marin; Dolores Vilas; Cristóbal Langdon; Isam Alobid; Mauricio López-Chacón; Antje Haehner; Thomas Hummel; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2018-06-15       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.